Daiwa Securities Group
FULC icon

Daiwa Securities Group’s Fulcrum Therapeutics FULC Stock Holding History

Daiwa Securities Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-180
Closed -$2K – 1278
2025
Q4 		$2K Buy
+180
New +$1.83K ﹤0.01% 1307
2024
Q4 		– Sell
-138
Closed – – 1298
2024
Q3 		$0 Hold
138
– – ﹤0.01% 1299
2024
Q2 		$1K Hold
138
– – ﹤0.01% 1288
2024
Q1 		$1K Hold
138
– – ﹤0.01% 1294
2023
Q4 		$1K Hold
138
– – ﹤0.01% 1295
2023
Q3 		$1K Hold
138
– – ﹤0.01% 1252
2023
Q2 		$0 Hold
138
– – ﹤0.01% 1331
2023
Q1 		$0 Hold
138
– – ﹤0.01% 1307
2022
Q4 		$1K Hold
138
– – ﹤0.01% 1268
2022
Q3 		$1K Hold
138
– – ﹤0.01% 1287
2022
Q2 		$1K Hold
138
– – ﹤0.01% 1288
2022
Q1 		$3K Hold
138
– – ﹤0.01% 1219
2021
Q4 		$2K Hold
138
– – ﹤0.01% 1282
2021
Q3 		$4K Buy
138
+86
+165% +$1.63K ﹤0.01% 1193
2021
Q2 		$1K Hold
52
– – ﹤0.01% 1190
2021
Q1 		$1K Hold
52
– – ﹤0.01% 1196
2020
Q4 		$1K Buy
+52
New +$588 ﹤0.01% 1175

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Daiwa Securities Group's FULC Position: Q1 2026 in Review

Daiwa Securities Group sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 180 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in FULC in Q4 2020 and held it in 17 quarters. The position peaked at $4K in Q3 2021. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Daiwa Securities Group reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 180 Fulcrum Therapeutics shares in Q1 2026, an estimated $2K.
  • Daiwa Securities Group first reported a position in Fulcrum Therapeutics in Q4 2020 and held it in 17 quarters.
  • Daiwa Securities Group's Fulcrum Therapeutics position peaked at $4K in Q3 2021.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.